Brokerages Set MDxHealth SA (NASDAQ:MDXH) Target Price at $2.17

Posted by Stanley Muller on Sep 16th, 2026

MDxHealth SA (NASDAQ:MDXH – Get Free Report) has been assigned an average recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $2.1667.

Several brokerages have issued reports on MDXH. BTIG Research lowered their price target on shares of MDxHealth from $4.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 21st. Weiss Ratings downgraded shares of MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Lake Street Capital set a $3.00 target price on shares of MDxHealth and gave the company a “buy” rating in a research report on Friday, August 14th. Finally, Wall Street Zen raised shares of MDxHealth to a “sell” rating in a research note on Saturday, August 15th.

View Our Latest Stock Report on MDxHealth

MDxHealth Stock Down 4.8%

MDxHealth stock opened at $0.67 on Wednesday. The business has a 50 day moving average price of $0.57 and a two-hundred day moving average price of $1.33. MDxHealth has a 12 month low of $0.40 and a 12 month high of $5.33. The stock has a market cap of $33.32 million, a price-to-earnings ratio of -0.93 and a beta of 1.57.

MDxHealth (NASDAQ:MDXH – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The firm had revenue of $27.21 million for the quarter, compared to analyst estimates of $26.14 million. On average, analysts expect that MDxHealth will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently modified their holdings of MDXH. Perkins Capital Management Inc. grew its position in MDxHealth by 7.1% in the first quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after acquiring an additional 97,500 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of MDxHealth by 21.8% during the first quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after acquiring an additional 54,600 shares during the period. Bank of America Corp DE boosted its stake in shares of MDxHealth by 213.9% in the 1st quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of MDxHealth in the 2nd quarter worth about $82,000.

About MDxHealth

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.